China's Inmagene Biopharmaceuticals Closes $21m Series B Funding Business News Asia. : Inmagene Biopharmaceuticals, one of China’s immunology drug development companies, has closed a $21 million Series B financing, led by Vertex Ventures China, and co-invested by Panacea Venture, Kunlun Capital, SCVC and a few other investors. The Series B financing will be mainly used to conduct global clinical trials, research and development, and product in-licensing activities. To date, Inmagene has raised over $40 million financing. Inmagene is a leading drug development company focused on immunology-related therapeutic areas. Its management team has strong global experience and is deeply rooted in China.